Review: Occult hepatitis C virus infection: Still remains a controversy

Journal of Medical Virology

Volumn 86, Issue 9, 2014, Pages 1491-1498

  Dzekova Vidimliski, Pavlina ^a   Nikolov, Igor ^a   Matevska Geshkovska, Nadica ^b   Dimovski, Aleksandar ^b   Rostaing, Lionel ^c   Sikole, Aleksandar ^a  

^a University Hospital of Nephrology   (Macedonia)

^b SS Cyril and Methodius University Faculty of Pharmacy   (Macedonia)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

HCV antibodies; HCV RNA; Liver cells; Occult hepatitis C; Peripheral blood mononuclear cells

Indexed keywords

HEPATITIS C VIRUS ANTIBODY; HEPATITIS C VIRUS RNA; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA; HEPATITIS C ANTIBODY;

ANTIVIRAL THERAPY; BLOOD SAMPLING; CELLULAR IMMUNITY; FOLLOW UP; GRAFT RECIPIENT; HEMODIALYSIS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; KIDNEY GRAFT; LIMIT OF DETECTION; LIVER BIOPSY; LIVER CELL; LIVER FUNCTION TEST; OCCULT HEPATITIS C VIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRAL CLEARANCE; VIRUS PARTICLE; VIRUS REPLICATION; BLOOD; GENETICS; HEPACIVIRUS; IMMUNOLOGY; RENAL REPLACEMENT THERAPY;

HEPATITIS C VIRUS;

HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; RENAL DIALYSIS; RNA, VIRAL;

EID: 84904043572     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23979     Document Type: Review

References (45)

1. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernández N, González-Parra E, Alcazar JM, Sánchez C, Diez-Baylón JC, Martinez P, Bartolomé J, Carreño V. 2008. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19:2288-2293.
2. Bartolomé J, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Quiroga JA, Palacios R, Carreño V. 2007. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 81:7710-7715.
3. Blackard JT, Kemmer N, Sherman KE. 2006. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences. Hepatology 44:15-22.
4. Carreno V. 2006. Occult hepatitis C virus infection: A new form of hepatitis C. World J Gastroenterol 12:6922-6925.
5. Carreno V, Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Bartolome J, Castillo I. 2006. Detection of hepatitis C virus (HCV) RNA in the liver of healthy anti-HCV antibody-positive, serum HCV-RNA negative patients with normal alanine aminotransferase levels. J Infect Dis 194:53-60.
6. Carreno V, Bartolome J, Castillo I, Quiroga JA. 2008. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 18:139-157.
7. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V. 2004. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189:7-14.
8. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V. 2006. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 43:1277-1283.
9. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. 2010. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol 82:1554-1559.
10. Centers for Disease Control and Prevention. 2001. Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR Recomm Rep 50:1-43.
11. Chen AY, Zeremski M, Chauhan R, Jacobson IM, Talal AH, Michalak TI. 2013. Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon a-2b and ribavirin therapy. PLoS ONE 8:e80078.
12. Fabrizi F, Martin P. 2008. Occult hepatitis C virus infection in hemodialysis. J Am Soc Nephrol 19:2248-2250.
13. Fowell AJ, Sheron N, Rosenberg WM. 2008. Renal hepatitis C in the absence of detectable serum or hepatic virus. Liver Int 28:889-891.
14. Gallegos-Orozco JF, Rakela J, Rosati MJ, Vargas HE, Balan V. 2008. Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy. Dig Dis Sci 53:2564-2568.
15. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374.
16. Halfon P, Bourlière M, Ouzan D, Sène D, Saadoun D, Khiri H, Pénaranda G, Martineau A, Oulès V, Cacoub P. 2008. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol 46:2106-2108.
17. Hoare M, Gelson WT, Rushbrook SM, Curran MD, Coleman N, Davies SE, Alexander GJ. 2008. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology 48:1737-1745.
18. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P, HCV Collaborative Group. 2004. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 19:904-909.
19. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L. 2003. Evidence that clearance of hepatitis C virus RNA after alpha interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14:2092-2098.
20. Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S, Sadigh ZA, Alavian SM. 2013. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 13:e11290.
21. Laskus T, Wilkinson J, Gallegod-Orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. 2004. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 127:764-776.
22. Laskus T, Operskalski EA, Radkowski M, Wilkinson J, Mack WJ, de Giacomo M, Al-Harthi L, Chen Z, Xu J, Kovacs A. 2007. Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis 195:124-133.
23. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P. 2004. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127:924-936.
24. Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. 2008. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 80:1720-1722.
25. MacParland SA, Pham TN, Guy CS, Michalak TI. 2009. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 49:1431-1441.
26. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, Giuily N, Castelnau C, Cardoso AC, Asselah T, Féray C, Nicolas-Chanoine MH, Bedossa P, Marcellin P. 2008. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135:821-829.
27. Melon S, Galarraga MC, Villar M, Laures A, Boga JA, de Oña M, Gomez E. 2005. Hepatitis C virus reactivation in anti-hepatitis C virus positive renal transplant recipients. Transplant Proc 37:2083-2085.
28. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. 2003. Hepatitis C and renal disease: An update. Am J Kidney Dis 42:631-657.
29. Muazzam AG, Qureshi S, Mansoor A, Mansoor A, Ali L, Iqbal M, Siddiqi S, Khan KM, Mazhar K. 2011. Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy. Genet Vaccines Ther 9:14.
30. Nicot F, Kamar N, Mariamé B, Rostaing L, Pasquier C, Izopet J. 2010. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 23:594-601.
31. Pardo M, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Perez-Mota A, Carreno V. 2006. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther 23:1153-1159.
32. Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Carreño V. 2007. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J Viral Hepat 14:36-40.
33. Pearlman BL, Traub N. 2011. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clin Infect Dis 52:889-900.
34. Pham TN, Michalak TI. 2006. Occult hepatits C virus persistence: Identification and characteristics. MLO Med Lab Obs 38:20-22.
35. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. 2004. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78:5867-5874.
36. Pham TN, Macparland SA, Coffin CS, Lee SS, Bursey FR, Michalak TI. 2005. Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 86:657-666.
37. Pham TN, Mulrooney-Cousins PM, Mercer SE, MacParland SA, Inglot M, Zalewska M, Simon K, Michalak TI. 2007. Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection. J Viral Hepat 14:537-548.
38. Pham TN, King D, MacParland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. 2008. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 134:812-822.
39. Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI. 2012. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat 19:103-111.
40. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V. 2006. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 80:10972-10979.
41. Radkowski M, Horban A, Gallegos-Orozco JF, Pawelczyk A, Jablonska J, Wilkinson J, Adair D, Laskus T. 2005. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis 191:1730-1733.
42. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. 2005. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41:106-114.
43. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567.
44. Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D, Bannachak D, Nelson KE. 2008. Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol 80:808-815.
45. van der Meer A, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. 2012. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308:2584-2595.